No clear survival benefit of azacitidine for lower‐risk myelodysplastic syndromes: A retrospective study of Nagasaki

The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using dat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Toriyama, Eo, Hata, Tomoko, Yokota, Ken‐ichi, Chiwata, Masahiko, Kamijo, Rena, Hashimoto, Miki, Taguchi, Masataka, Horai, Makiko, Matsuo, Masatoshi, Matsuo, Emi, Takasaki, Yumi, Kawaguchi, Yasuhisa, Itonaga, Hidehiro, Sato, Shinya, Ando, Koji, Sawayama, Yasushi, Taguchi, Jun, Imaizumi, Yoshitaka, Tsushima, Hideki, Jo, Tatsuro, Yoshida, Shinichiro, Moriuchi, Yukiyoshi, Miyazaki, Yasushi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7734160/
https://ncbi.nlm.nih.gov/pubmed/32939867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14653
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia